NCT00391521 - AS703569 Phase I in Patients With Solid Tumours | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Solid Tumors

Interventions

DRUG

AS703569

Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle

DRUG

AS703569

Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle

DRUG

AS703569

Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle

Trial Locations (1)

EMD Serono Medical Information Office, Rockland